biopharmaceutical company Algernon Pharmaceuticals Inc AGNPF recently announced plan for a Phase 1 clinical trial of DMT in human stroke just got approval from the Foundation Assessment Ethics Biomedical Research (BEBO)an independent ethics committee for medical research.

The process will be carried out on Center for Human Drug Research (CHDR) in Leiden, The Netherlands, with screening to begin shortly and expected dosing to begin in Q4 2022.

Because the center had previously led DMT studies, Algernon initially hired the CHDR and its affiliated pharmacy at Leiden University Medical Center to develop that IVF intended for the phase 1 study. The partners then decided to submit an ethics and clinical trials application to do so advance the DMT stroke research program as quickly as possible.

The focus of the research is based on the results of several preclinical studies that have already been shown This particular psychedelic helps moderate tissue damage and promotes neurogenesis and structural and functional neural plasticityall key factors involved in the brain’s ability to form and reorganize synaptic connections, and therefore helps that Brain healing after injury.

In addition, Algernon’s preclinical study of cortical neuron outgrowth in mice showed that sub-psychedelic doses of DMT reduced the Growth of cortical neurons by up to 40%.

Previous phase 1 DMT trials have therefore been positive No serious adverse events or safety issues are expected resulting from the present study. Still, Algernon is conducting a phase 1 study and is not going directly into a phase 2 study as the center of research is on prolonged intravenous infusion of DMT, duration not yet clinically studied.

The resulting data from this study should help the company Better plan phase 2 studies in acute stroke and rehabilitationthe “important information about dosage and duration of our new DMT IVF …